Pathways’ Picks January 29: Coronavirus Dx, Next-Gen Coverage, EU Meetings, And More

article image
ARTICLE SUMMARY:

Medicare moves to clear up a next-generation sequencing coverage mix-up; the escalating coronavirus outbreak is driving attention toward diagnostic emergency-use approval policies in China and the US; EU policymakers issued a 2020 meeting agenda, and more in this week’s Pathways’ Picks, Market Pathways’ weekly roundup of the most important global medtech regulatory, reimbursement, and policy news. Pictured: A railway station in China's Wuhan Province, ground zero for the coronavirus.

The Centers for Medicare and Medicaid Services removed coverage restrictions on next-generation sequencing testing as a treatment guide in early-stage inherited cancers. Diagnostics are also increasingly a focus of governments trying to respond to the coronavirus outbreak. Those IVD policy developments lead off this week’s Pathways’ Picks.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.


Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to Market Pathways:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to Market Pathways
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite

Questions?

We're here to help! Please contact us at: